Oncternal Therapeutics, Inc.
ONCTDelisted Mar 17, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001260990
Oncternal Therapeutics, Inc. was delisted on Mar 17, 2025; its insiders filed their last Form 4 on Jun 24, 2024; 23 institutions reported holding it in 13F filings for Q3 2024, worth $471.0K in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Oncternal Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
ONCT is no longer listed, and 13F filings after Q3 2024 list far fewer holders. See Q3 2024
- Institutional holders
- 4
- −19 vs. Q3 2024
- Shares held
- 1.89K
- −355.4K (−99.5%) vs. Q3 2024
- Total value
- $10
- −$471.0K (−100.0%) vs. Q3 2024
- New holders
- 1
- 0 more added
- Sold out
- 20
- 0 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ONCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $75 |
| Q1 2026 | 1 | $74 |
| Q4 2025 | 2 | $169 |
| Q3 2025 | 1 | $73 |
| Q2 2025 | 1 | $74 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 4 | $10 |
| Q3 2024 | 23 | $471.0K |
| Q2 2024 | 26 | $3.67M |
| Q1 2024 | 24 | $4.05M |
| Q4 2023 | 41 | $4.53M |
| Q3 2023 | 52 | $2.81M |
| Q2 2023 | 53 | $3.26M |
| Q1 2023 | 55 | $7.86M |
| Q4 2022 | 59 | $9.31M |
| Q3 2022 | 61 | $8.79M |
| Q2 2022 | 75 | $12.6M |
| Q1 2022 | 79 | $18.6M |
| Q4 2021 | 84 | $30.5M |
| Q3 2021 | 77 | $56.8M |
| Q2 2021 | 85 | $65.2M |
| Q1 2021 | 67 | $82.5M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Oncternal Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Steward Partners Investment Advisory, LLC | 15 | $8 | 0.00% | 00.0% | Unchanged |
| Nemes Rush Group LLC | 3 | $2 | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 1,829 | $0 | 0.00% | 00.0% | Unchanged |
| Parvin Asset Management, LLC | 40 | $0 | 0.00% | +40 | New |
| Vanguard Group Inc | 0 | $0 | 0.00% | −139,884−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −61,205−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −39,706−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −25,879−100.0% | Sold out |
| Pasadena Private Wealth, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −17,905−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −14,152−100.0% | Sold out |
| Quantum Private Wealth, LLC | 0 | $0 | 0.00% | −13,187−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −12,276−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,822−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,221−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1,111−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −408−100.0% | Sold out |
| North Star Investment Management Corp. | 0 | $0 | 0.00% | −250−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −182−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −1−100.0% | Sold out |